EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c

EPIRUS Biopharma (NASDAQ: EPRS) reported Q1 EPS of ($0.39), $0.04 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $25 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c